Forte Biosciences, Inc.

This early-stage trial tests a new drug called FB102 in 64 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Half will get the drug and half a placebo, both given by IV. The main goal is to check safety and see if the drug helps bring back ski…

This early-stage trial tests a drug called FB102 in 32 adults with severe to very severe alopecia areata, a condition causing significant hair loss. Half receive the drug and half a placebo, all by IV. The main goal is to check safety, but researchers will also measure hair regro…

This study tests a new biologic drug called FB102 in 100 adults with celiac disease who already follow a strict gluten-free diet. Participants will receive either FB102 or a placebo and then undergo a controlled gluten challenge to see if the drug can reduce intestinal damage and…